RNA-seq profiling of A549 cells with sgRNA knockouts that confer prexasertib resistance

A549 cells with FOXM1 or LIN54 sgRNA knockout, which confers resistance to the CHK1 inhibitor prexasertib, were generated. These cells and control (empty vector) cells were synchronized in S phase, released for 1 hour and treated with 100 nM prexasertib or DMSO (vehicle) for 2 hours. RNA-seq profiling was performed to identify drug-induced perturbations in gene expression in these cells. Overall design: RNA-seq profiling of A549 cells with sgRNA knockouts that confer prexasertib resistance, compared to control A549 cells, with or without prexasertib treatment